Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TLR2 | O60603 | 4/20 | 0.41 |
| ▸ | TPSAB1 | Q15661 | 1/20 | 0.38 |
| ▸ | SIRT5 | Q9NXA8 | 1/20 | 0.37 |
| ▸ | SIRT2 | Q8IXJ6 | 6/20 | 0.37 |
| ▸ | SIRT1 | Q96EB6 | 5/20 | 0.37 |
| ▸ | PTPN1 | P18031 | 2/20 | 0.36 |
| ▸ | SIRT3 | Q9NTG7 | 3/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30992313 | 0.92 | CASP3 (0.40) | TLR2SIRT5SIRT2SIRT1SIRT3 | |
| SCHEMBL21738670 | 0.92 | CASP3 (0.40) | TLR2SIRT5SIRT2SIRT1SIRT3 | |
| SCHEMBL21738589 | 0.92 | CASP3 (0.40) | TLR2SIRT5SIRT2SIRT1SIRT3 | |
| SCHEMBL30781796 | 0.90 | TLR2 (0.46) | TLR2TPSAB1SIRT5SIRT2SIRT1 | |
| SCHEMBL23880545 | 0.89 | TLR2 (0.39) | TLR2TPSAB1PTPN1 | |
| SCHEMBL30509100 | 0.89 | TLR2 (0.39) | TLR2TPSAB1PTPN1 | |
| SCHEMBL31035902 | 0.89 | TLR2 (0.39) | TLR2TPSAB1PTPN1 | |
| SCHEMBL84146 | 0.88 | TLR2 (0.39) | TLR2TPSAB1PTPN1 | |
| SCHEMBL27213335 | 0.88 | EPOR (0.35) | SIRT5SIRT2SIRT1 | |
| SCHEMBL30781664 | 0.88 | SIRT5 (0.36) | TLR2TPSAB1SIRT5SIRT2SIRT1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4548937-A1 | ANTIBODY-DRUG COMPLEX | Eisai R&D Management Co., Ltd. (JP) | 2025-05-07 | — | — | EP | disclosed |
| US-20240148895-A1 | ANTIBODY-DRUG CONJUGATE | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2024-05-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240148895-A1 | ANTIBODY-DRUG CONJUGATE | ANTXR2, FCGR1A, HAX1 | TLR2 1069/4885TPSAB1 1343/4885SIRT5 3214/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.